Comparing Dapagliflozin and Sitagliptin for Liver Fat in Diabetic Liver Transplant Patients
Official title: Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation: a Randomized Controlled Trial
Run by Medanta, The Medicity, India · NCT05042505 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing whether the medications dapagliflozin or sitagliptin can help reduce liver fat in people with diabetes who have had a liver transplant.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Medanta, The Medicity, India Academic / other |
| Locations | 1 site (Gurgaon, Haryana) |
| Trial ID | NCT05042505 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with type 2 diabetes who are undergoing or have undergone liver transplantation.
✕Probably not a fit
Patients with type 1 diabetes or significant kidney dysfunction may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of dapagliflozin versus sitagliptin on liver fat accumulation and body composition in patients with diabetes mellitus who have undergone liver transplantation. The study aims to enroll 100 patients, including those with pre-transplant type 2 diabetes and new-onset diabetes after transplantation. Participants will receive either dapagliflozin or sitagliptin, and their outcomes will be assessed through various demographic, clinical, and laboratory parameters. The trial is conducted following ethical guidelines and requires informed consent from all participants.
Why it matters
Potential benefit: If successful, this study could provide insights into effective management strategies for diabetes in liver transplant patients, potentially reducing liver fat accumulation.
How similar studies have gone: While there is limited data on the specific use of dapagliflozin and sitagliptin in this population, SGLT-2 inhibitors have shown promise in managing liver fat in other contexts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosis of diabetes (pre-transplantation type 2 diabetes or new onset diabetes after transplantation) 2. Subjects taking insulin and/or metformin and/or sulfonylurea. 3. Body mass index (BMI) \>=18.5 kg/m2 Exclusion Criteria: 1. Type 1 diabetes 2. Estimated glomerular filtration rate (eGFR) \<45 ml/min/1.73 m2, calculated by the Chronic Kidney Disease - Epidemiology (CKD-EPI) equation 3. Liver aminotransferases \>3 times the upper limit of the reference range (upper normal limit AST or ALT \>=40 units/L) 4. History of recurrent urinary tract infection 5. History or current acute or chronic pancreatitis 6. Pregnancy 7. Presence of major contraindications to magnetic resonance imaging (cardiac pacemakers, claustrophobia, foreign bodies and implanted medical devices with ferromagnetic properties).
Where it's running
-
Division Of Endocrinology & Diabetes, Medanta The Medicity
Gurgaon, Haryana, India Recruiting
Study contacts
- Study coordinator: Mr Surender, M.Sc
- Email: yadavsurender89@gmail.com
- Phone: 01244141414
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman
A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
-
SugarVita 2.0: a 12-week digital game for adults with type 2 diabetes
This 12-week pilot tests SugarVita 2.0, a serious digital game, to see if it helps adults with type 2 diabetes manage their condition and feel more confident.
-
Linking social care with healthcare to help manage chronic diseases
This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.
-
Transcutaneous and topical photobiomodulation for diabetic foot ulcers
This phase 2 trial tests whether combining transcutaneous and topical photobiomodulation helps heal foot ulcers in adults with diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.